Detalhe da pesquisa
1.
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
Lancet
; 399(10338): 1886-1901, 2022 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35569466
2.
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
N Engl J Med
; 376(5): 417-428, 2017 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28146658
3.
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.
Eur Urol
; 84(2): 156-163, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37179241
4.
Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.
J Clin Oncol
; 40(27): 3172-3179, 2022 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35737923
5.
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.
J Clin Oncol
; 37(14): 1159-1168, 2019 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30860948
6.
Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408.
Adv Radiat Oncol
; 2(4): 608-614, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29204528
7.
Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.
J Clin Oncol
; 33(4): 332-9, 2015 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25534388